In ground­break­ing move, FDA ap­proves My­ovan­t's re­l­u­golix as the first once-a-day pill for ad­vanced prostate can­cer

My­ovant Sci­ences $MY­OV won’t be get­ting coal in their stock­ing this Christ­mas.

The Swiss biotech, for­mer­ly part of the Vivek Ra­maswamy fam­i­ly of Vants, won FDA ap­proval of its re­l­u­golix drug on Fri­day af­ter­noon for the treat­ment of ad­vanced prostate can­cer. It’s the first oral hor­mone ther­a­py ap­proved for the in­di­ca­tion, reg­u­la­tors said, and the drug will be mar­ket­ed as Or­govyx. PDU­FA ac­tion had been sched­uled for Dec. 20.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN